Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Urigen Pharmaceuticals, Inc.

Urigen Pharmaceuticals, Inc. is a private clinical stage urology focused specialty pharmaceutical company. Our team is focused on developing innovative products to amerliorate the cause and symtoms associated with Urological ailments, specifically Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS). Our leading phase 2 program is URG101 for treating acute pain associated with IC/BPS flares. Urigen is raising $15M to fund End of Phase 2 meeting with FDA and IPO/exit activities.

  • Date:Tuesday, February 12
  • Time:9:30 AM - 9:45 AM
  • Room:Gramercy
  • Location:7th Floor
  • Session Type:Company Presentation
  • Company Presentation - Presentation Type:Privately Funded Company
  • Submission ID:23501
  • Goal for Presentation:Investor Introductions
  • Company Website:www.urigen.com
  • Company HQ City:North Brunswick
  • Company HQ State:New Jersey
  • Company HQ Country:United States
  • Total Amount Raised to Date, in All Rounds:$10 MM
  • Size of Last Investment Round:$2 MM
  • CEO/Top Company Official:Dan Vickery, MBA PhD
  • Year Founded:2014
  • Main Therapeutic Focus:Reproductive/Sexual Health
  • Lead Product in Development:URG101
  • Development Phase of Primary Product:Phase III
  • Number Of Unlicensed Products (For Which You Are Seeking Partners):3
  • Additional Information/Comments:Urigen's additional programs include URG501, an oral treatment for IC/BPS and URG801, an instillation product for Radiation and Hemorrhagic Cystitis.
Speakers
Dan Vickery
Urigen Pharmaceuticals, Inc.
Back